Website: Bioverativ
Business Area(s): 


Bioverativ will be an independent, publicly-traded, global biotechnology technology focused on the discovery, research, development and commercialization of therapies for hemophilia and other blood disorders. It is on track to launch in early 2017.

As a focused and independent company, we believe that Bioverativ will be uniquely positioned to drive progress and advance the standard of care for people living with hemophilia and other blood disorders. The new company will build on Biogen’s work that recently brought the first new treatment options to hemophilia patients in nearly two decades.

Cambridge MA
United States